Similarly, synNotch circuits developed by Witzen et al., in which ALPPL2-specific synNotch receptors induce CARs targeting mesothelin or HER2, demonstrated superior tumor control in xenograft models of solid cancers compared to constitutively expressed CARs [97]. This evidence concerns the gene MSLN and neoplasm.